SPRB

Spruce is a clinical-stage biopharma with zero product revenue and no approved products — FY2025 revenue was $0.00 (down from $4.91M in FY2024 and $10.1M in FY2023), and it has never sustained a revenue line. The entire equity value rests on a single lead asset, tralesinidase alfa (TA-ERT) for MPS IIIB / Sanfilippo Syndrome Type B, after the company pivoted away from tildacerfont in November 2024. The clinical setup is genuinely attractive on paper — FDA Breakthrough Therapy plus Rare Pediatric, Fast Track and Orphan designations, no approved therapy for the disease, and a BLA planned for Q4 2026 — but every dollar of upside is contingent on regulatory success that the provided data cannot handicap. This is a binary bet, which the rubric treats as unknowable risk.

The balance sheet is the disqualifier. Management explicitly states that cash of $48.9M as of 12/31/2025, even with the January 2026 Avenue Capital loan proceeds, 'will be insufficient to fund our operations and debt obligations for at least 12 months' — a textbook going-concern flag. The company has burned $33.3M of operating cash in FY2025 and carries a $289.2M accumulated deficit against just $42.5M of equity, an ROE of -91.7%. It has raised $343.1M since inception and continues to lean on serial dilutive financings (a $50M private placement in October 2025 alone). More financing is not optional; it is required, and it will come at whatever price the market dictates ahead of a make-or-break BLA.